ArticleToxicology reports2024
Cilostazol geno-protective effects mitigate carbamazepine-induced genotoxicity in human cultured blood lymphocytes.
Article in Toxicology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cilostazol protective effect on nedaplatin-induced genotoxicity in cultured human lymphocytes.Toxicology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbamazepine is one of the most widely used antiepileptic drugs. Carbamazepine has been shown to be toxic to cells. Cilostazol, an antiplatelet agent, has known antioxidant, antiproliferative, anti-inflammatory, and anti-tumor effects. Objective: This study aimed to explore whether carbamazepine and cilostazol exert genotoxic and/or cytotoxic effects in human cultured blood lymphocytes and the impact of combining both drugs on such effects. Methods: Genotoxicity was examined using sister chromatid exchange (SCE) assay, while cytotoxicity was evaluated by cell kinetic assays (mitotic and proliferative indices). Results: Study findings have revealed that carbamazepine markedly increased SCEs (p<0.01), while cilostazol significantly decreased their frequencies (p<0.01). In addition, the frequency of SCEs of the combination of both drugs was similar to that of the control group (p>0.05). Carbamazepine increased the cell proliferative index (p<0.01) while cilostazol decreased it (p<0.01). The proliferative index was normalized to the control level when both drugs were combined. Conclusion: We suggest that cilostazol has the potential to protect human lymphocytes from carbamazepine-induced toxic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.